There is a global drive towards the repositioning of known drugs for cancer treatment due to high failure rate and cost of new drugs. Disulfiram (DS), an old anti-alcoholism drug, possesses excellent anticancer activity with low toxicity to normal cells. Unfortunately, the application of DS for cancer treatment is hindered by the extremely short half-life of DS in the bloodstream.
Prof. Wang's Experimental Cancer Therapeutic Research Group (ECTRG) at University of Wolverhampton (UoW) successfully used cutting-edge nano-drug-delivery technologies to extend the half-life of DS in the bloodstream, which manifests strong anticancer efficacy in animal models. This scientific breakthrough led to the establishment of a spin-out company Disulfican Ltd.
Disulfican has now developed a GMP quality human applicable nano-encapsulated DS as a novel anti-cancer therapy and are developing a pre-clinical data package prior to clinical trials. Our efforts have provided significant opportunity to develop an affordable effective anticancer drug within a shorter period of time which will be highly beneficial to cancer patients, NHS and the UK society.
To enrich the quality of life of cancer patients and their families by developing and delivering innovative, effective and affordable anticancer drugs.
Disulfican focuses on repurposing an old anti-alcoholism drug into an anticancer medicine.
Strategy: Achieve orphan drug designation for our proprietary formulation of disulfiram as a treatment for mesothelioma and glioblastoma which are considered as 'orphan diseases' because of their rarity and lack of effective treatments. Extend applications to other cancers with appropriate formulations in our development pipeline.